14 Amendments of Nathalie COLIN-OESTERLÉ related to 2019/2816(RSP)
Amendment 21 #
Citation 26 a (new)
- having regard to the Commission Communication of 11 December 2019 entitled ‘The European Green Deal’ (COM(2019)0640),
Amendment 43 #
Recital C a (new)
Ca. whereas population increase and climate change will have an impact on the quantity of quality of water resources and on water treatment and re-use;
Amendment 47 #
Recital D
D. whereas the excessive and incorrectinappropriate use of antibiotics, particularly in livestock farming, and more generally poor practices in both human and veterinary medicine, have progressively rendered antimicrobial resistance a massive threat to human and animal health;
Amendment 72 #
Recital L a (new)
La. whereas human and animal health players and professionals, patients, industry, waste management and water treatment operators, etc., have a role to play in reducing the impact of pharmaceutical products on the environment;
Amendment 85 #
Paragraph 5
5. Considers that a holistic approach is needed to tackle pharmaceutical pollution, including all the actors concerned, is needed to tackle the negative impact of pharmaceutical products in the environment, taking into account the entire life cycle of drugs; stresses that regulatory actions have to be taken in line with the precautionary principle; highlights that the polluter pays principle should apply, primarily covering at all stages of the life cycle of pharmaceutical products, covering, primarily but not exclusively, the manufacturing process, but also incentivising better prescription practices and consumer behaviour;
Amendment 100 #
Paragraph 7
7. Recalls that studies have shown that residue from pharmaceutical products areis especially present in water bodies, and that they are ineffectively filtered byit is not completely removed by conventional wastewater treatment plants;
Amendment 134 #
Paragraph 12
12. Calls on the Member States to share best practices in the preventive use of antibiotics and to apply in full and, if necessary, reinforce the ‘One Health Action Plan Against Antimicrobial Resistance’; reaffirms the positions expressed in its resolution of 13 September 2018 on a European One Health Action Plan against Antimicrobial Resistance;
Amendment 139 #
Paragraph 13
13. Calls on the Member States and on the Commission to promote awareness- raising campaigns and training courses among veterinaries and physicianhealthcare professionals on the prudent use of pharmaceuticals, particularly of antimicrobials; calls on actors in the pharmaceutical supply chain to contribute to providing to patients with clear, sufficient information on how incorrectly disposed medicines may negatively impact the environment; calls for on-pack labelling in the form of an appropriate pictogramme to inform consumers how to properly dispose of unused medicines;
Amendment 151 #
Paragraph 15
15. Calls on Member States and the Commission to support theresearch, development and innovation of pharmaceuticals intrinsicallywhich are equally effective for patients and less harmful for the environment (‘greener pharmaceuticals’), which degrade more readily, into harmless substances, in wastewater treatment plants and the environment; calls on the Member States and the Commission to boost funding for this;
Amendment 156 #
Paragraph 15 a (new)
15a. Calls on the Member States and all stakeholders concerned to make use of EU programmes to invest in technology aimed at improving the effectiveness of the disposal of pharmaceutical products and antimicrobial-resistant genes whilst ensuring that such products are just as effective in terms of meeting patients' needs;
Amendment 174 #
Paragraph 20
20. Points to the important role of procurement policy in promoting greener pharmaceuticals which respect the environment; calls on the Commission to develop clear guidance on this issue; by including, for example, environmental criteria in addition to simple economic criteria;
Amendment 211 #
Paragraph 28
28. Considers that a review of Directive 86/278/EEC on sewage sludge is long overdue; calls on the Commission to evaluate and, if necessary given the results obtained, to make a legislative proposal to review and update Directive 86/278/EEC no later than by the end of 20201, not least so as to avoid that pharmaceutical residues are spread onto fields;
Amendment 220 #
Paragraph 30
30. Calls for the Member States to implement and fully enforcement of the existing provisions with regard to take- back schemes for unused medicines;
Amendment 252 #
Paragraph 37
37. Recalls that pharmaceutical environmental information plays a key role for risk management and that this type of information should be made available to relevant stakeholders; therefore calls on the Commission and the relevant authorities to set up a secure, centralised database enabling all the actors concerned to have access to the results of the environmental risk assessments of products;